Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial ...

A California jury ruled on Wednesday that Axonics did not infringe three of Medtronic’s patents related to sacral neuromodulation. The latest decision resolves a lawsuit that has been ongoing since ...

US Medical device giant Axonics has announced that it has secured market clearance from Australia’s Therapeutic Goods Administration (TGA) for its R20 rechargeable sacral neuromodulation (SNM) system ...

“I am grateful for Eileen’s leadership as interim CEO, and the continued dedication of Paula Newell, founder & board director ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 ...

Based in Irvine, device maker Axonics Inc. reported fourth-quarter revenue climbed 61% to $85.6 million to $86 million, topping the $78.1 million expected by analysts. “This quarter’s record revenue ...

Barely 6 months after raising a $38.5 million Series B to advance its neuromodulation implant to treat overactive bladder and fecal dysfunction, Axonics Modulation Technologies won a CE mark for the ...

Shares jump after the medical device maker announces that it has secured an important regulatory win. The FDA granted premarket approval for the Axonics r-SNM System as a treatment for urinary urge ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral ...

Axonics was $74 a share on Monday, its highest price since its 2018 initial public offering. The medical-device maker is coming off a strong second quarter and an improved yearly financial outlook.